Our lead treatment candidate for Alzheimer’s disease (AD), AD101, is a small synthetic molecule that modulates the activity of specific T-type calcium channels to promote the release of acetylcholine, a neurotransmitter, in the brain.
AD101 is being developed to work in concert with Donepezil (Aricept®), the current global standard of care for Alzheimer’s disease since 1996. Donepezil improves both cognition and global function in all stages of AD (mild through severe).
AD101 increases acetylcholine release, while Donepezil preserves acetylcholine by inhibiting an enzyme which normally breaks it down. When administered in combination, AD101 has demonstrated additive improvement over that of Donepezil alone in both animal models and in randomized, double-blind, placebo-controlled Phase 2 clinical trials in AD patients.
AD101 and Donezepil increase neurotransmission through these separate, yet complementary mechanisms, working together addressing the core symptoms of AD: loss of independent global function and impaired cognition.
Improved global function and cognition is achieved via a known pathway — increased neurotransmission.
AD101 increases ACh release Donepezil (Aricept®) preserves ACh = Additive Improvement in Neurotransmission
AD101 is a tablet that can be administered once a day by mouth.
For more detail on completed AD101 Phase 2 clinical trials, please visit the PIPELINE page.
CLINICAL AND PRECLINICAL DATA PRESENTED AT CTAD 2022:
- AD101-the clinical profile of a new, first-in-class treatment for Alzheimer’s Disease
- AD101 improves cognitive function in animal models of memory and learning impairment
- Effects of T-type calcium channel modulator AD101 on the accumulation of Beta Amyloid, Tau, and polyubiquitinated proteins in animal models of Alzheimer’s Disease